Table 3.
The associations between PKM2 expression and other prognostic factors
| PKM2 expression | |||
|---|---|---|---|
| Negativea (N=54) |
Positivea (N=61) |
p valueb | |
| Tumor grade | 0.33 | ||
| 1 | 7 (13 %) | 8 (13 %) | |
| 2 | 27 (50 %) | 38 (62 %) | |
| 3 | 20 (37 %) | 15 (25%) | |
| Tumor stage | 0.49 | ||
| I-IIA | 12 (22 %) | 17 (28 %) | |
| IIBIV | 42 (78 %) | 44 (72 %) | |
| Surgical margin status | 0.099 | ||
| Negative | 34 (63 %) | 47 (77 %) | |
| Positive | 20 (37 %) | 14 (23 %) | |
| Perineural invasion | 0.3 | ||
| Negative | 12 (22 %) | 9 (15 %) | |
| Positive | 42 (78 %) | 52 (85 %) | |
| Peripancreatic extension | 0.29 | ||
| Negative | 10 (19%) | 7 (11 %) | |
| Positive | 44 (81 %) | 54 (89 %) | |
| Adjuvant chemotherapy | 0.28 | ||
| No | 17 (32 %) | 13 (23 %) | |
| Yes | 36 (68 %) | 44 (77 %) | |
| CA 19–9 level | 205 (98–551) | 85 (32–336) | 0.034 |
| Lymph node ratio | 0.195 (0.036–0.435) | 0.091 (0.00–0.286) | 0.077 |
| Overall survival, months | 10.6 (6.6–19.0) | 16.6 (9.8–35.8) | 0.008 |
| Age at surgery | 68.8 (60.7–72.9) | 63.6 (56.5–73.0) | 0.22 |
a
Frequency (percent) for categorical variables and median (IQR) for continuous variables
b
Pearson test for categorical variables and Wilcoxon rank-sum test for continuous variables